Related Experiment Videos
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin
Patrick C Ma1, Erik Schaefer, James G Christensen
1Section of Hematology/Oncology, Department of Medicine, Pritzker School of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
Summary
PHA665752, a c-MET inhibitor, effectively reduced cancer cell growth and migration. Combined with rapamycin, it showed cooperative therapeutic potential for treating non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- c-MET receptor tyrosine kinase is a target for cancer therapy.
- TPR-MET is an oncogenic variant of MET used to model c-MET inhibitors.
- Targeted therapies aim to inhibit specific molecular pathways in cancer.
Purpose of the Study:
- To characterize the small molecule c-MET inhibitor PHA665752.
- To evaluate PHA665752's efficacy against TPR-MET-transformed cells.
- To assess the synergistic effect of PHA665752 with rapamycin in targeted cancer therapy.
Main Methods:
- Assessed PHA665752's effects on cell growth, motility, migration, apoptosis, and cell cycle.
- Determined PHA665752's impact on MET phosphorylation and downstream signaling (p-AKT, p-S6K).
- Evaluated the combined efficacy of PHA665752 and rapamycin on TPR-MET and c-MET-expressing H441 NSCLC cells.
Main Results:
- PHA665752 potently inhibited growth (IC50 < 0.06 µM), induced apoptosis, and caused cell cycle arrest in TPR-MET cells.
- PHA665752 suppressed constitutive cell motility and migration, and inhibited MET phosphorylation and downstream signaling.
- Combination therapy with PHA665752 and rapamycin demonstrated cooperative inhibition of cancer cell growth.
Conclusions:
- PHA665752 is a potent and selective c-MET inhibitor with significant biological and biochemical activity against TPR-MET-transformed cells.
- PHA665752 exhibits activity against H441 NSCLC cells.
- The combination of c-MET inhibitor PHA665752 and rapamycin warrants further in vivo investigation for treating c-MET expressing cancers, including NSCLC.